Here we listed a selection of original contribution of the company’s founder published in high-ranking international peer-reviewed journals related to the specific topics.
Medical translational research takes up problems related to our patients into the lab. Here, a multi-disciplinary team in basic science helps to make results useful for practical applications to enhance our understanding of disease, develop new diagnostics and translate our findings into new therapeutic options. Curiosity, precision, well-founded and sound scientific knowledge with a good feeling for relevant problems characterise academic research with clinical applicability. It is now well-known that circulating angiogenic cells play an indespensible role in vascular regeneration and organ preservation. Our work has been reproduced and cited manifold.
Despite the knowledge that eating slowly significantly lowers meal energy intake and hunger ratings, individuals do not implement this behaviour. After dieting, usually weight regain is the consequense. Not in the case of a novel non-invasive medical device, where patients with increased cardiovascular risk profile had long-term weight reduction in a prospective trial. Currently, the results of the prospective, randomised, single-blinded, are eagerly awaited to confirm the initial results.
The ACE-Study was widely acceclaimed and received great international interest. This investigator-initiated study broadened the indication of Enoxaparin. In this randomised, prospective multicentre-study Enoxaparin showed non-inferior to unfractionated heparin and phenprocoumon in TEE-guided cardioversion of persistent non-valvular atrial fibrillation.
Pattern of clinical disease caused by human parvovirus B19 (B19V) is generally a self-limiting subclinical disorder. However, in certain individuals B19V is a fatal disease. B19 V is the most common viral pathogen associated with inflammatory cardiomyopathy. Interestingly, B19V infection is restricted to cardiac endothelial cells, but not cardiomyocytes in this disease. B19V infection of endothelial cells results in apoptosis, the programmed cell death. Patients with B19V cardiomyopathy present with endothelial dysfunction and show elevated numbers of circulating apoptotic endothelial cells. How can B19V persist in the heart over long time periods? What are the mechanisms of damage in B19V-infected bone marrow-derived cells? These findings are being published shortly in a high-ranking journal.
You may find the impact of the publications (i.e. citation counts, etc.) on: